Penn Capital Management Company, LLC Halozyme Therapeutics, Inc. Transaction History

Penn Capital Management Company, LLC

$983 Million
Q3 2024

A detailed history of Penn Capital Management Company, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Penn Capital Management Company, LLC holds 266,167 shares of HALO stock, worth $14.8 Million. This represents 1.55% of its overall portfolio holdings.

Number of Shares

266,167

Previous 300,670 11.48%

Holding current value

$14.8 Million

Previous $15.7 Million 3.28%

% of portfolio

1.55%

Previous 1.65%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $1.77 Million - $2.22 Million	-34,503 Reduced 11.48%	266,167 $15.2 Million
Q2 2024 Aug 13, 2024	BUY	$37.81 - $52.4 $1.06 Million - $1.47 Million	28,074 Added 10.3%	300,670 $15.7 Million
Q1 2024 May 15, 2024	SELL	$33.68 - $41.95 $233,873 - $291,300	-6,944 Reduced 2.48%	272,596 $11.1 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $1.5 Million - $1.9 Million	-45,167 Reduced 13.91%	279,540 $10.3 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $1.39 Million - $1.68 Million	38,217 Added 13.34%	324,707 $12.4 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $23,255 - $29,752	768 Added 0.27%	286,490 $10.3 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $9.39 Million - $15.9 Million	285,722 New	285,722 $10.9 Million
Q4 2022 Feb 13, 2023	SELL	$40.06 - $59.44 $1.16 Million - $1.73 Million	-29,061 Reduced 9.21%	286,523 $16.4 Million
Q3 2022 Dec 09, 2022	BUY	$38.53 - $51.78 $9.64 Million - $13 Million	250,230 Added 382.88%	315,584 $12.5 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $9.03 Million - $12.1 Million	-234,471 Reduced 78.2%	65,354 $2.64 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $2.8 Million - $3.62 Million	74,976 Added 33.35%	299,825 $13.2 Million
Q1 2022 May 17, 2022	SELL	$31.97 - $41.06 $1.74 Million - $2.24 Million	-54,574 Reduced 19.53%	224,849 $8.34 Million
Q4 2021 Feb 17, 2022	SELL	$31.82 - $40.75 $349,097 - $447,068	-10,971 Reduced 3.78%	279,423 $11.3 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $518,652 - $625,834	13,482 Added 4.87%	290,394 $11.8 Million
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $310,525 - $410,223	7,995 Added 2.97%	276,912 $12.6 Million
Q1 2021 May 13, 2021	BUY	$39.51 - $51.45 $1.09 Million - $1.42 Million	27,555 Added 11.42%	268,917 $11.2 Million
Q4 2020 Feb 16, 2021	SELL	$25.81 - $43.62 $1.32 Million - $2.23 Million	-51,208 Reduced 17.5%	241,362 $10.3 Million
Q3 2020 Nov 16, 2020	BUY	$25.74 - $29.63 $63,912 - $73,571	2,483 Added 0.86%	292,570 $7.76 Million
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $96,590 - $159,358	5,944 Added 2.09%	290,087 $7.84 Million
Q1 2020 May 13, 2020	BUY	$13.9 - $21.83 $3.95 Million - $6.2 Million	284,143 New	284,143 $5.12 Million

Others Institutions Holding HALO

# of Institutions

538

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.75B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Penn Capital Management Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Penn Capital Management Company, LLC with notifications on news.

Account

Penn Capital Management Company, LLC Halozyme Therapeutics, Inc. Transaction History